The Leukemia & Lymphoma Society (LLS) will give Celator Pharmaceuticals $3.7 million to fund a Phase IIb trial with CPX-351 liposome injection for treatment of adults with acute myeloid leukemia (AML). Celator expects to start patient enrollment in this study in the current quarter in the U.S. and Canada.
This mid-stage study is designed to be a multicenter, randomized, open-label trial of CPX-351 versus intensive salvage therapy in adult patients 60 years or younger with AML in first relapse.
“Celator has discovered a novel way to deliver and enhance the activity of agents that have been the standard of care in AML for decades,” according to Louis DeGennaro, Ph.D., LLS' CSO. “There have been many attempts to improve outcomes in this patient population with little success. The data collected on CPX-351 to date, and the enthusiasm of clinical investigators involved in that research, suggest that Celator's approach holds real promise to advance the treatment of AML.”